Serum KIM-1 as an early biomarker for hypertensive nephropathy

Key Points

• Serum KIM-1 levels in hypertensive nephropathy patients were significantly higher than in those with hypertension or healthy controls.
• The mean KIM-1 level was 4.44 ng/mL in nephropathy patients compared to 1.55 ng/mL in hypertensive patients and 1.21 ng/mL in healthy individuals.
• The study involved 135 participants, categorized into control, hypertensive without nephropathy, and hypertensive with nephropathy groups.
• Findings support KIM-1 as a promising biomarker for the early detection and monitoring of hypertensive nephropathy.